QuidelOrtho Corporation (LON:0A55)
43.50
-0.14 (-0.31%)
At close: Jan 31, 2025
QuidelOrtho Revenue
QuidelOrtho had revenue of $692.80M USD in the quarter ending March 30, 2025, a decrease of -2.56%. This brings the company's revenue in the last twelve months to $2.76B, down -3.42% year-over-year. In the year 2024, QuidelOrtho had annual revenue of $2.78B, down -7.17%.
Revenue (ttm)
$2.76B
Revenue Growth
-3.42%
P/S Ratio
0.68
Revenue / Employee
$418.89K
Employees
6,600
Market Cap
1.45B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 2.78B | -214.90M | -7.17% |
Dec 31, 2023 | 3.00B | -268.20M | -8.21% |
Jan 1, 2023 | 3.27B | 1.57B | 92.28% |
Jan 2, 2022 | 1.70B | 36.90M | 2.22% |
Jan 3, 2021 | 1.66B | 1.13B | 210.66% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
QuidelOrtho News
- 7 days ago - QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs - PRNewsWire
- 5 weeks ago - QuidelOrtho to discontinue Savanna platform development - Seeking Alpha
- 5 weeks ago - QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics - PRNewsWire
- 7 weeks ago - QuidelOrtho to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - Benzinga
- 2 months ago - SA analyst downgrades: QDEL, AMCX, PLYM, DAY - Seeking Alpha
- 2 months ago - QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade) - Seeking Alpha
- 2 months ago - Quidelortho sees $30M-$40M tariff impact offset, maintains 2025 guidance - Seeking Alpha